游以勒,王胜锋.磷酸二酯酶5抑制剂与肿瘤发病关联研究的新进展[J].中华流行病学杂志,2023,44(9):1486-1490 |
磷酸二酯酶5抑制剂与肿瘤发病关联研究的新进展 |
Progress in research of association between phosphodiesterase 5 inhibitors and cancer incidence |
收稿日期:2023-02-13 出版日期:2023-09-14 |
DOI:10.3760/cma.j.cn112338-20230213-00072 |
中文关键词: 磷酸二酯酶5抑制剂 肿瘤 发病风险 关联研究 机制 |
英文关键词: Phosphodiesterase 5 inhibitors Cancer Incidence risk Association study Mechanism |
基金项目:国家重点研发计划(2022YFC3602900);国家自然科学基金(82173616) |
|
摘要点击次数: 1918 |
全文下载次数: 559 |
中文摘要: |
伴随磷酸二酯酶5抑制剂(PDE5Is)用药数量的逐年增加,大量人群研究提示PDE5Is与特定肿瘤发病风险存在潜在关联。本文针对PDE5Is与各种肿瘤发病风险关联及机制研究进行系统梳理,已有研究进行Meta分析,结果显示,使用PDE5Is可能与黑色素瘤(RR=1.11,95%CI:1.02~1.22)、基底细胞癌(RR=1.16,95%CI:1.13~1.20)发病风险增加相关,鳞状细胞癌结果尚不一致,与前列腺癌(OR=0.71,95%CI:0.40~1.29)无统计学关联,对结直肠癌(RR=0.85,95%CI:0.76~0.95)可能具有预防作用。建议未来针对现有研究的经验及不足开展进一步深入探索。 |
英文摘要: |
With the increased use of phosphodiesterase 5 inhibitors (PDE5Is) over the past years, several population based studies have suggested a potential association between PDE5Is and the risk for specific cancers. This paper systematically summarizes the current status of relatedstudies. Meta-analyses on current research indicated that the use of PDE5Is might be associated with the increased risk for melanoma (RR=1.11, 95%CI:1.02-1.22) and basal cell carcinoma (RR=1.16, 95%CI:1.13-1.20), but not for prostate cancer (OR=0.71, 95%CI:0.40-1.29), and might have chemoprophylaxis effect on colorectal cancer (RR=0.85, 95%CI:0.76-0.95). However, results of squamous cell carcinoma were still inconsistent. Further exploration based on the experience and limitations of current research is suggested. |
查看全文
Html全文
查看/发表评论 下载PDF阅读器 |
|
关闭 |